Heterogeneous treatment effects of metformin on risk of dementia in patients with type 2 diabetes: A longitudinal observational study.
Alzheimers Dement
; 20(2): 975-985, 2024 Feb.
Article
de En
| MEDLINE
| ID: mdl-37830443
ABSTRACT
INTRODUCTION:
Little is known about the heterogeneous treatment effects of metformin on dementia risk in people with type 2 diabetes (T2D).METHODS:
Participants (≥ 50 years) with T2D and normal cognition at baseline were identified from the National Alzheimer's Coordinating Center database (2005-2021). We applied a doubly robust learning approach to estimate risk differences (RD) with a 95% confidence interval (CI) for dementia risk between metformin use and no use in the overall population and subgroups identified through a decision tree model.RESULTS:
Among 1393 participants, 104 developed dementia over a 4-year median follow-up. Metformin was significantly associated with a lower risk of dementia in the overall population (RD, -3.2%; 95% CI, -6.2% to -0.2%). We identified four subgroups with varied risks for dementia, defined by neuropsychiatric disorders, non-steroidal anti-inflammatory drugs, and antidepressant use.DISCUSSION:
Metformin use was significantly associated with a lower risk of dementia in individuals with T2D, with significant variability among subgroups.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Démence
/
Diabète de type 2
/
Metformine
Limites:
Humans
Langue:
En
Journal:
Alzheimers Dement
Année:
2024
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique